The cardioprotective effects of an antiemetic drug, tropisetron, on cardiomyopathy related to doxorubicin

Cardiovascular Toxicology

Volumn 12, Issue 4, 2012, Pages 318-325

  Alimoradi, Houman ^a   Barzegar Fallah, Anita ^b   Hassanzadeh, Gholamreza ^c   Mohammadi Rick, Sanaz ^d   Asadi, Firouzeh ^b   Delfan, Bahram ^e   Abbasi, Ata ^c   Dehpour, Ahmad Reza ^b  

^a AHVAZ JUNDISHAPUR UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d ISLAMIC AZAD UNIVERSITY   (Iran)

^e LORESTAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Cardioprotective; Cardiotoxicity; Doxorubicin; Rat; Tropisetron

Indexed keywords

CREATINE KINASE; CREATINE KINASE MB; DOXORUBICIN; LACTATE DEHYDROGENASE; TROPISETRON; TROPONIN I;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARDIOMYOPATHY; CARDIOTOXICITY; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; CREATINE KINASE MB BLOOD LEVEL; DISEASE MARKER; ELECTROCARDIOGRAPHY; HEART MUSCLE CONTRACTILE FORCE; HEART MUSCLE CONTRACTILITY; HEART PAPILLARY MUSCLE; HEART PROTECTION; HEART WEIGHT; HISTOPATHOLOGY; LACTATE DEHYDROGENASE BLOOD LEVEL; MALE; MORTALITY; NONHUMAN; PRIORITY JOURNAL; RAT; TROPONIN I BLOOD LEVEL; WEIGHT REDUCTION;

ANIMALS; ANTIEMETICS; CARDIOMYOPATHIES; CARDIOTONIC AGENTS; DOXORUBICIN; ELECTROCARDIOGRAPHY; INDOLES; MALE; MYOCARDIAL CONTRACTION; ORGAN CULTURE TECHNIQUES; RANDOM ALLOCATION; RATS; RATS, SPRAGUE-DAWLEY; TREATMENT OUTCOME; VENTRICULAR FUNCTION, LEFT;

RATTUS;

EID: 84870558053     PISSN: 15307905     EISSN: 15590259     Source Type: Journal    
DOI: 10.1007/s12012-012-9175-x     Document Type: Article

References (29)

1. Fisher, P. W., Salloum, F., Das, A., Hyder, H., & Kukreja, R. C. (2005). Phosphodiesterase-5 inhibition with sildenafil attenuates cardiomyocyte apoptosis and left ventricular dysfunction in a chronic model of doxorubicin cardiotoxicity. Circulation, 111, 1601.
2. Fajardo, G., Zhao, M., Powers, J., & Bernstein, D. (2006). Differential cardiotoxic/cardioprotective effects of beta-adrenergic receptor subtypes in myocytes and fibroblasts in doxorubicin cardiomyopathy. Journal of Molecular and Cellular Cardiology, 40, 375.
3. Singal, P. K., & Iliskovic, N. (1998). Doxorubicin-induced cardiomyopathy. New England Journal of Medicine, 339, 900-905.
4. Villani, F., Monti, E., Piccinini, F., Favalli, L., Lanza, E., Rozza, D. A., et al. (1986). Relationship between doxorubicin-induced ECG changes and myocardial alterations in rats. Tumori, 72, 323.
5. Rossi, F., Filippelli, W., Russo, S., Filippelli, A., & Berrino, L. (1994). Cardiotoxicity of doxorubicin: Effects of drugs inhibiting the release of vasoactive substances. Pharmacology and Toxicology, 75, 99-107.
6. Sauter, K., Wood, L. J., Wong, J., Iordanov, M., & Magun, B. E. (2011). Doxorubicin and daunorubicin induce processing and release of interleukin-1 through activation of the NLRP3 inflammasome. Cancer Biology & Therapy, 11, 1008.
7. Kalivendi, S. V., Konorev, E. A., Cunningham, S., Vanamala, S. K., Kaji, E. H., Joseph, J., et al. (2005). Doxorubicin activates nuclear factor of activated T-lymphocytes and Fas ligand transcription: Role of mitochondrial reactive oxygen species and calcium. Biochemical Journal, 389, 527.
8. Wang, S., Kotamraju, S., Konorev, E., Kalivendi, S., Joseph, J., & Kalyanaraman, B. (2002). Activation of nuclear factor-kappaB during doxorubicin-induced apoptosis in endothelial cells and myocytes is pro-apoptotic: The role of hydrogen peroxide. Biochemical Journal, 367, 729.
9. Scuderi, P. E. (2003). Pharmacology of antiemetics. International Anesthesiology Clinics, 41, 41.
10. Fiebich, B., Akundi, R., Lieb, K., Candelario-Jalil, E., Gmeiner, D., Haus, U., et al. (2004). Antiinflammatory effects of 5-HT 3 receptor antagonists in lipopolysaccharide-stimulated primary human monocytes. Scandinavian Journal of Rheumatology, 33, 28-32.
11. Vega, L., Munoz, E., Calzado, M. A., Lieb, K., Candelario-Jalil, E., Gschaidmeir, H., et al. (2005). The 5-HT3 receptor antagonist tropisetron inhibits T cell activation by targeting the calcineurin pathway. Biochemical Pharmacology, 70, 369-380.
12. Rahimian, R., Dehpour, A. R., Fakhfouri, G., Khorramizadeh, M. R., Ghia, J. E., Seyedabadi, M. et al. (2011). Tropisetron upregulates cannabinoid Cb1 receptors in cerebellar granule cells: Possible involvement of Calcineurin. Brain Research, 1417, 1-8.
13. Rahimian, R., Daneshmand, A., Mehr, S. E., Barzegar-Fallah, A., Mohammadi-Rick, S., Fakhfouri, G. et al. (2011). Tropisetron ameliorates ischemic brain injury in an embolic model of stroke. Brain Research, 1392, 101-109.
14. Mousavizadeh, K., Rahimian, R., Fakhfouri, G., Aslani, F. S., & Ghafourifar, P. (2009). Anti-inflammatory effects of 5-Ht3 receptor antagonist, tropisetron on experimental colitis in rats. European Journal of Clinical Investigation, 39(5), 375-383.
15. Rahimi-Balaei, M., Momeny, M., Babaeikelishomi, R., Ejtemaei Mehr, S., Tavangar, S. M., & Dehpour, A. R. (2010). The modulatory effect of lithium on doxorubicin-induced cardiotoxicity in rat. European Journal of Pharmacology, 641, 193-198.
16. Herman, E., Mhatre, R., Lee, I., Vick, J., & Waravdekar, V. (1971). A comparison of the cardiovascular actions of daunomycin, adriamycin and N-acetyldaunomycin in hamsters and monkeys. Pharmacology, 6, 230-241.
17. El-Missiry, M. A., Othman, A. I., Amer, M. A., & Abd El-Aziz, M. A. (2001). Attenuation of the acute adriamycin-induced cardiac and hepatic oxidative toxicity by N-(2-mercaptopropionyl) glycine in rats. Free Radical Research, 35, 575-581.
18. Chatterjee, K., Zhang, J., Honbo, N., & Karliner, J. S. (2009). Doxorubicin cardiomyopathy. Cardiology, 115, 155-162.
19. Yi, X., Bekeredjian, R., DeFilippis, N. J., Siddiquee, Z., Fernandez, E., & Shohet, R. V. (2006). Transcriptional analysis of doxorubicin-induced cardiotoxicity. American Journal of Physiology. Heart and Circulatory Physiology, 290, 1098.
20. Boucek, R. J., Jr, Dodd, D. A., Atkinson, J. B., Oquist, N., & Olson, R. D. (1997). Contractile failure in chronic doxorubicininduced cardiomyopathy 1. Journal of Molecular and Cellular Cardiology, 29, 2631-2640.
21. Weinberg, L. E., & Singal, P. K. (1987). Refractory heart failure and age-related differences in adriamycin-induced myocardial changes in rats. Canadian Journal of Physiology and Pharmacology, 65, 1957-1965.
22. Kalivendi, S. V., Kotamraju, S., Zhao, H., Joseph, J., & Kalyanaraman, B. (2001). Doxorubicin-induced apoptosis is associated with increased transcription of endothelial nitric-oxide synthase. Journal of Biological Chemistry, 276, 47266.
23. Doroshow, J. H. (1983). Effect of anthracycline antibiotics on oxygen radical formation in rat heart. Cancer Research, 43, 460.
24. Hogan, P. G., Chen, L., Nardone, J., & Rao, A. (2003). Transcriptional regulation by calcium, calcineurin, and NFAT. Genes and Development, 17, 2205.
25. Wilkins, B. J., Dai, Y. S., Bueno, O. F., Parsons, S. A., Xu, J., Plank, D. M., et al. (2004). Calcineurin/NFAT coupling participates in pathological, but not physiological, cardiac hypertrophy. Circulation Research, 94, 110.
26. van Rooij, E., Doevendans, P. A., de Theije, C. C., Babiker, F. A., Molkentin, J. D., & De Windt, L. J. (2002). Requirement of nuclear factor of activated T-cells in calcineurin-mediated cardiomyocyte hypertrophy. Journal of Biological Chemistry, 277, 48617.
27. De Bruijn, K. (1993). The development of tropisetron in its clinical perspective. Annals of Oncology, 4, S19.
28. Seide, M., Ulrich-Merzenich, G., Fiebich, B., Candelario-Jalil, E., Koch, F., & Vetter, H. (2004). Tropisetron inhibits serotonininduced PGE2 release from macrophage-like synovial cells in serum-free tissue culture. Scandinavian Journal of Rheumatology. Supplement, 33, 33.
29. Stratz, T., & Muller, W. (2004). Treatment of systemic sclerosis with the 5-HT 3 receptor antagonist tropisetron. Scandinavian Journal of Rheumatology, 33, 59-62.